文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

通腑泻肺汤通过调控微小RNA-146a抑制THP-1细胞程序性死亡受体-1/程序性死亡配体1信号通路的机制

[Mechanism of Tongfu Lifei decoction inhibiting the programmed death-1/programmed death-ligand 1 signaling pathway in THP-1 cells by regulating microRNA-146a].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论体外实验显示通腑泻肺汤通过上调miR-146a抑制THP-1细胞PD-1/PD-L1通路并减少TNF-α、IL-6分泌,作者认为其可调节脓毒症免疫屏障。

该研究在体外用1 mg/L LPS刺激THP-1细胞18小时构建炎症模型,先以MTT法筛选通腑泻肺汤(TFL)对THP-1细胞的无毒剂量(0-0.04 mL/mL无毒性,0.08、0.16 mL/mL有毒性),再以0.01、0.02、0.04 mL/mL干预24小时。结果显示0.02、0.04 mL/mL TFL显著降低TNF-α和IL-6水平,并呈剂量依赖性下调PD-1/PD-L1通路蛋白(PD-1、PD-L1、PI3K、p-Akt),同时显著降低miR-146a表达(miR-146b、miR-155无显著变化)。在0.04 mL/mL TFL基础上加入miR-146a抑制剂可显著逆转TFL对炎症因子和通路蛋白的抑制作用。作者结论认为TFL通过调控miR-146a抑制PD-1/PD-L1信号通路,调节体外脓毒症细胞炎症模型的免疫屏障,从而保护LPS诱导的THP-1细胞。

要点

  • 体外THP-1细胞经1 mg/L LPS刺激18小时构建炎症模型,TFL 0.02、0.04 mL/mL干预24小时可显著降低TNF-α和IL-6(均P<0.01)。
  • TFL 0.04 mL/mL组PD-1、PD-L1、PI3K、p-Akt蛋白表达均显著低于炎症模型组(均P<0.01),且呈一定剂量依赖性。
  • TFL 0.01、0.02、0.04 mL/mL组miR-146a表达均显著降低(均P<0.01),miR-146b、miR-155无显著变化。
  • 加入miR-146a抑制剂可显著逆转TFL对炎症因子和PD-1/PD-L1通路蛋白的抑制作用(P<0.01或P<0.05)。
  • MTT法显示0-0.04 mL/mL TFL对THP-1细胞无毒性,0.08、0.16 mL/mL组细胞存活率显著低于炎症模型组。

适用人群与场景

  • 体外培养的人单核细胞白血病细胞THP-1,经1 mg/L LPS刺激18小时构建的体外炎症模型;未涉及急诊或ICU患者。

诊断标准与关键阈值

  • 体外炎症模型构建:THP-1细胞以1 mg/L LPS孵育18小时,ELISA检测TNF-α和IL-6分泌较空白对照组显著升高即判定模型构建成功。
  • TFL无毒剂量筛选:以0、0.005、0.01、0.02、0.04、0.08、0.16 mL/mL TFL(每毫升培养基加入不同剂量TFL溶液,生药含量1 kg/L)干预24小时,MTT法检测细胞存活率,0-0.04 mL/mL对THP-1细胞无毒性,0.08、0.16 mL/mL有毒性。

处置流程与药物剂量

  • TFL干预剂量:炎症模型细胞分别以0.01、0.02、0.04 mL/mL TFL干预24小时;最大无毒浓度0.04 mL/mL用于机制实验。
  • miR-146a抑制剂干预:在0.04 mL/mL TFL基础上加入100 nmol/L miR-146a抑制剂,干预24小时。

研究设计与关键结果

  • 研究类型为体外细胞实验;THP-1细胞以1 mg/L LPS刺激18小时构建炎症模型,与空白对照组比较TNF-α和IL-6分泌显著升高,提示模型构建成功。
  • MTT法显示0-0.04 mL/mL TFL对THP-1细胞无毒性;0.08 mL/mL和0.16 mL/mL TFL组细胞存活率显著低于炎症模型组,提示超过0.04 mL/mL的TFL剂量对THP-1细胞有毒性。
  • 与炎症模型组比较,0.01 mL/mL TFL对TNF-α和IL-6无显著影响;0.02 mL/mL和0.04 mL/mL TFL显著降低TNF-α[ng/L:95.89±8.55、70.73±11.70 vs. 137.10±7.19]和IL-6[ng/L:23.03±2.55、16.58±1.72 vs. 32.60±2.55],均P<0.01。
  • 与炎症模型组比较,不同剂量TFL组THP-1细胞PD-1/PD-L1通路蛋白表达显著降低并呈一定剂量依赖性;0.04 mL/mL TFL组PD-1蛋白(PD-1/β-actin)0.28±0.04 vs. 1.00±0.10,PD-L1蛋白(PD-L1/β-actin)0.54±0.05 vs. 1.00±0.08,PI3K蛋白(PI3K/β-actin)0.28±0.03 vs. 1.00±0.08,p-Akt蛋白(p-Akt/Akt)0.38±0.04 vs. 1.00±0.10,均P<0.01。
  • 与炎症模型组比较,0.01、0.02、0.04 mL/mL TFL组THP-1细胞miR-146a表达显著降低(2-ΔΔCt:0.46±0.11、0.31±0.13、0.23±0.14 vs. 1.01±0.18,均P<0.01),miR-146b和miR-155表达无显著变化。
  • 与炎症模型组比较,TFL组THP-1细胞TNF-α和IL-6分泌显著降低;miR-146a抑制剂可显著逆转TFL对炎症因子的抑制作用,与TFL组比较差异有统计学意义[TNF-α(ng/L):138.55±10.30 vs. 72.33±10.59,IL-6(ng/L):31.35±3.98 vs. 15.75±3.76,均P<0.01]。
  • 与炎症模型组比较,TFL组THP-1细胞PD-1/PD-L1通路蛋白表达显著降低;TFL+miR-146a抑制剂组通路蛋白表达显著高于TFL组[PD-1蛋白(PD-1/β-actin):0.85±0.09 vs. 0.37±0.04,PD-L1蛋白(PD-L1/β-actin):0.83±0.08 vs. 0.55±0.06,PI3K蛋白(PI3K/β-actin):0.85±0.09 vs. 0.63±0.06,p-Akt蛋白(p-Akt/Akt):0.98±0.10 vs. 0.75±0.07,均P<0.05]。

证据类型、等级与局限

  • 证据类型:体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文为体外细胞实验,作者认为TFL通过调控miR-146a抑制THP-1细胞PD-1/PD-L1信号通路,调节体外脓毒症细胞炎症模型的免疫屏障,从而保护LPS诱导的THP-1细胞;未给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To explore the protective effect and mechanism of Tongfu Lifei decoction (TFL) on human monocytic leukemia cell THP-1 induced by lipopolysaccharide (LPS).

METHODS: (1) THP-1 cells were cultured in vitro, and incubated with 1 mg/L LPS for 18 hours to construct an in vitro THP-1 cell inflammation model. Other THP-1 cells were taken as blank control group. Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of tumor necrosis factor-α(TNF-α) and interleukin-6 (IL-6) secreted by cells. (2) THP-1 cells were divided into seven groups and treated with 0, 0.005, 0.01, 0.02, 0.04, 0.08, and 0.16 mL/mL TFL for 24 hours (added different dosages of TFL solution per milliliter of culture medium, with a crude drug content of 1 kg/L). The cell survival rate was detected using methyl thiazolyl tetrazolium (MTT) colorimetric method, and the intervention dosage of TFL for its non-toxic effect on THP-1 cells was screened. (3) Another THP-1 cells were divide into inflammatory model group and 0.01, 0.02, and 0.04 mL/mL TFL groups according to the intervention dosage of TFL screened by MTT colorimetry. After 24 hours of intervention, the levels of TNF-α and IL-6 secreted by cells were measured using ELISA. Western blotting was used to detect the expressions of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) signaling pathway proteins in cells. Real time fluorescence quantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expressions of microRNAs (miR-146a, miR-146b, miR-155) in cells. (4) The maximum non-toxic concentration of TFL (0.04 mL/mL) on the THP-1 cell was selected as the intervention dose. THP-1 cells were divided into inflammation model group, TFL group, TFL+miR-146a inhibitor group, TFL+miR-146b inhibitor group, and TFL+miR-155 inhibitor group. The inflammation model group was not given any drug intervention. The other inhibitor groups were added 100 nmol/L corresponding inhibitor. After 24 hours of intervention, the levels of TNF-α and IL-6 secreted by cells were measured using ELISA. Western blotting was used to detect the expressions of PD-1/PD-L1 signaling pathway proteins in cells.

RESULTS: (1) Compared with the blank control group, the levels of TNF-α and IL-6 secreted by cells in the inflammatory model group were significantly increased, indicating the successful construction of the THP-1 inflammatory cell model in vitro. (2) 0-0.04 mL/mL TFL had no toxic effect on THP-1 cells. However, the survival rates of cells in the 0.08 mL/mL and 0.16 mL/mL TFL groups were significantly lower than those in the inflammation model group, indicating that TFL dosages exceeding 0.04 mL/mL had toxic effects on THP-1 cells. (3) Compared with the inflammation model group, 0.01 mL/mL TFL had no significant effect on the levels of TNF-α and IL-6 secreted by THP-1 cells, while intervention with 0.02 mL/mL and 0.04 mL/mL TFL significantly reduced the levels of TNF-α and IL-6 secreted by cells [TNF-α(ng/L): 95.89±8.55, 70.73±11.70 vs. 137.10±7.19, IL-6 (ng/L): 23.03±2.55, 16.58±1.72 vs. 32.60±2.55, all P < 0.01]. Compared with the inflammation model group, the expressions of PD-1/PD-L1 signaling pathway proteins in THP-1 cells in different dosages of TFL groups were significantly reduced, and showed a certain dosage dependence. The expressions of the pathway proteins in the 0.04 mL/mL TFL group were significantly lower than those in the inflammation model group [PD-1 protein (PD-1/β-actin): 0.28±0.04 vs. 1.00±0.10, PD-L1 protein (PD-L1/β-actin): 0.54±0.05 vs. 1.00±0.08, phosphoinositide 3-kinase (PI3K) protein (PI3K/β-actin): 0.28±0.03 vs. 1.00±0.08, phosphorylated protein kinase B (p-Akt) protein (p-Akt/Akt): 0.38±0.04 vs. 1.00±0.10, all P < 0.01]. Compared with the inflammation model group, the expression of miR-146a in THP-1 cells in the 0.01, 0.02, and 0.04 mL/mL TFL groups was significantly reduced (2-ΔΔCt: 0.46±0.11, 0.31±0.13, 0.23±0.14 vs. 1.01±0.18, all P < 0.01), while there was no significant change in the expressions of miR-146b and miR-155. (4) Compared with the inflammation model group, the TFL group showed a significant decrease in the levels of TNF-α and IL-6 secreted by THP-1 cells. The miR-146a inhibitor could significantly reverse the inhibitory effect of TFL on inflammatory factors, and the difference was statistically significant as compared with the TFL group [TNF-α (ng/L): 138.55±10.30 vs. 72.33±10.59, IL-6 (ng/L): 31.35±3.98 vs. 15.75±3.76, both P < 0.01]. Compared with the inflammation model group, the expressions of PD-1/PD-L1 signaling pathway proteins in THP-1 cells in the TFL group were significantly reduced. The expressions of pathway proteins in cells in the TFL+miR-146a inhibitor group were significantly higher than those in the TFL group [PD-1 protein (PD-1/β-actin): 0.85±0.09 vs. 0.37±0.04, PD-L1 protein (PD-L1/β-actin): 0.83±0.08 vs. 0.55±0.06, PI3K protein (PI3K/β-actin): 0.85±0.09 vs. 0.63±0.06, p-Akt protein (p-Akt/Akt): 0.98±0.10 vs. 0.75±0.07, all P < 0.05].

CONCLUSIONS: TFL regulates the expression of miR-146a to inhibit the PD-1/PD-L1 signaling pathway in THP-1 cells, regulates the immune barrier of sepsis induced in cell inflammation model in vitro, and thus protects LPS induced THP-1 cells.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Lyu B, Li L, Huang R, et al. [Mechanism of Tongfu Lifei decoction inhibiting the programmed death-1/programmed death-ligand 1 signaling pathway in THP-1 cells by regulating microRNA-146a]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39586721. doi:10.3760/cma.j.cn121430-20240229-00180

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。